Baselake Partners, LP Acquires 5.3% Stake in Kezar Life Sciences, Inc.

On April 6, 2026, Baselake Partners, LP, along with Baselake Management, LLC and David Paolella, filed a Schedule 13G indicating a new passive ownership stake in Kezar Life Sciences, Inc. (KZR). The reporting persons collectively reported beneficial ownership of 391,862 shares of common stock, representing 5.3% of the company based on 7,371,527 shares outstanding as of March 23, 2026. The shares are held directly by Baselake Partners, LP, with Baselake Management, LLC serving as the investment manager and David Paolella acting as the managing member of the investment manager. Consequently, all three reporting persons share voting and dispositive power over the reported shares. The filing was triggered by an event on March 30, 2026, marking a significant increase from zero reported holdings previously. The reporting persons certified that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer.